CONCLUSION
Based on the pooled data obtained in this meta-analysis, it can be concluded that among adults with CKD, the oral adsorbent AST-120 offers no significant advantage over standard treatment in terms of reducing the incidence of mortality, ESRD, and doubling of serum creatinine. Further studies examining different dosages of AST-120 and its effect on different CKD stages are recommended.